Molecular Profiling of Breast Cancer Susceptibility of Obese or Insulin- 2 Resistant and Pre-Diabetic Patients Using ITLN1 and CD295 SNPs

: 32 Mutations in cluster of differentiation (CD) 295 gene, encoding class I cytokine 33 receptor, are associated with obesity and breast cancer (BC). SNPs in the adipocyte- 34 inferred novel cytokine intelectin 1 (ITLN1) remain understudied in connection to 35 CD295 polymorphisms and diabetes mellitus (DM) or a pre-diabetic state, as well as 36 to DNA damage seen in BC. We will explore whether CD295 (ID rs6700896) and 37 ITLN1 (rs rs952804) SNPs impact BC with or without DM, insulin resistance (IR) or 38 obesity. Effects of ITLN1 or CD295 polymorphism(s) on DNA damage in BC were 39 also examined. Blood samples from 170 women with BC (including 33 and 48 with 40 DM and pre-diabetes, respectively) and from 108 age-matched women in the control 41 group were collected. Plasma insulin, leptin, CD295, and ITLN1 levels were 42 measured by ELISA. DNA damage was assessed using an alkaline comet assay. 43 BC cases with clinical stage T II and positive LN as well as tumor histologic grade 44 III, presence of obesity, pre-diabetic events, DM or IR were associated with CD295 45 rs6700986 mutant homozygous (CC) and heterozygous (CT) genotype and ITLN1 46 rs952804 mutant heterozygous genotype (CT) (P ≤ 0.05).

for CD295 rs6700986 and ITLN1 rs952804, respectively, were associated with BC 27 events and risk (P ≤ 0.05). 28 • CD295 rs6700986 and ITLN1 rs952804 SNPs may be considered BC-associated 29 risk for G3, T2, +LN, obesity, pre-diabetic/diabetic and IR in BC patients. to DNA damage seen in BC. We will explore whether CD295 (ID rs6700896) and 37 ITLN1 (rs rs952804) SNPs impact BC with or without DM, insulin resistance (IR) or 38 obesity. Effects of ITLN1 or CD295 polymorphism(s) on DNA damage in BC were 39 also examined. Blood samples from 170 women with BC (including 33 and 48 with 40 DM and pre-diabetes, respectively) and from 108 age-matched women in the control 41 group were collected. Plasma insulin, leptin, CD295, and ITLN1 levels were 42 measured by ELISA. DNA damage was assessed using an alkaline comet assay. 43 recommendations of the Declaration of Helsinki (WMA 2013). Written informed 112 consent was obtained from all study subjects. 113

Inclusion criteria 114
Females diagnosed with invasive ductal carcinoma (IDC) for the first time at age 43 115 or older were included. A total of 170 postmenopausal female patients aged 43-75 116 were selected and the median age was 53 years-old. 117

Exclusion criteria 118
Patients having incomplete data or histopathologic diagnosis, as well as patients with 119 metastasis at the time of initial diagnosis were excluded. Males with BC were 120 excluded as were BC types other than IDC. Other exclusion criteria were: previous or 121 current history of acute or chronic viral hepatitis; malignant disease; acute infections; 122 pituitary, adrenal, thyroid, or pancreatic disease, or evidence of any other endocrine 123 disorders; or prolonged use of corticosteroids or sex hormones. 124

Control group 125
A group of 108 age-matched healthy controls (median age 53 years) with normal liver 126 enzyme levels and no clinical or laboratory evidence of BC was recruited during 127 routine wellness examinations. 128

Participant data 129
The demographic characteristics of the study subjects are summarized in Table 1a. 130 and a score of +3 as positive), grading and proliferation status as assessed by Ki  expressed as mean ± standard deviation (SD) in addition to the median (range) for 201 nonparametric data. To study the association between variables an odds ratio (OR) 202 was calculated. For categorical variables, a Chi-square test was used to make 203 comparisons between different groups. The best cutoff values for the investigated 204 parameter(s) (FSH) were calculated from ROC curves. Genetic analyses were also 205 conducted using unconditional logistic regression. Initially, we used univariate 206 analyses to examine possible associations between each polymorphism and cancer 207 grades (II and III) or T (I and II) or N (-/+), or DNA damage and associated metabolic 208 factors (e.g., insulin, HOMA-IR, and IR). We also conducted subgroup analyses to examine potential interactions by the levels of the pre-specified factors and the 210 studied SNPs. Based on the findings from our population, we computed the 211 frequencies of each allele using Hardy-Weinberg equilibrium (HWE) and online 212 software. A likelihood ratio test was performed to test significances. Correlations 213 were assessed using the Spearman correlation coefficient (r). Two-tailed analyses 214 were performed, and P values ≤ 0.05 were considered statistically significant. 215

RESULTS 216
A total of 278 individuals were recruited for this study, including 170 females with 217 BC, of whom 158 were insulin resistant (Table 1a). Among the BC patients, 132 were 218 obese. Of the obese BC patients, 88 were normoglycemic, 48 were pre-diabetic and 219 33 had DM. The healthy control group had 108 individuals, of which 40 and 68 were 220 lean and obese, respectively (Table 1a). 221

Clinical and biological analysis of the study population 222
Various anthropometric parameters, obesity and diabetes factors, and BC clinical 223 measures, as well as plasma levels of leptin, CD295, ITLN1 were collected (Table  224 1a), as was information concerning the SNPs under study and DNA damage 225 parameters for both the BC patients and the healthy controls (Table 1b)

Distribution of CD295 rs6700986 and ITLN1 rs95280 283 genotype variants among BC patient obesity/IR factors 284
The presence of obesity, IR or DM, as well as having experienced a pre-diabetic event 285 were associated with mutant homozygous (CC) (for obesity and IR only) and 286 heterozygous (CT) CD295 rs6700986 genotypes (P ≤ 0.05; Table 3). Also, obesity, 287 pre-diabetic event and being diabetic, in addition to IR were associated with BC cases 288 that were ITLN1 rs952804 mutant heterozygous (CT) (P ≤ 0.05; Table 3). 289

ITLN1 rs952804 genotypes and DNA damage parameters 299
Among DNA damage parameters, only tail DNA (%) and tail moment unit were 300 significantly (P ≤ 0.05) associated with CD295 rs6700986 mutant heterozygous (CT) 301 genotype and ITLN1 rs952804 mutant homozygous (TT) genotype (Table 5).   CD295 polymorphisms seen in this study. It should be noted that ITLN1 rs952804 394 mutant heterozygous (CT), specifically the T allele, was related to BC risk, DNA 395 damage and obesity, DM and IR. In addition, there was no statistically significant 396 difference between our observations and that predicted by the Hardy-Weinberg 397 principle for ITLN1, suggesting that the population was in Hardy-Weinberg 398 equilibrium (HWE) (data not shown). Thus, the null hypothesis is not rejected, and 399 we presume that the population is indeed in HWE, although additional study is 400 needed to contrast the findings for this locus with that of another study population. 401 There is currently no BC screening program in Egypt and in the absence of 402 population-based-cancer registries in developing nations, including Egypt, patients 403 with early pre-clinical illness may have been missed in our study. It is possible that 404 polymorphisms of CD295 or potentially ITLN1 could contribute to variations in BC